Eurofins Technologies Launches New Multiplex RT-PCR Respiratory Panel for SARS-CoV-2, Flu A, Flu B, RSV A and RSV B
01 Décembre 2021 - 09:00AM
Business Wire
Eurofins Technologies
announces the launch of two RT-PCR assays to accurately diagnose
respiratory diseases caused by SARS-CoV-2, Influenza virus or RSV.
Since initial symptoms produced by these pathogens are
indistinguishable, access to accurate and reliable tests will help
clinicians improve patient care.
These new CE-marked multiplex
kits have been specifically designed to detect and differentiate
three viral infections in the same PCR run. The Mplex
SARS-CoV-2+, Flu A, Flu B (C1) RT-PCR assay facilitates differentiation, in a
single reaction, between Influenza A, B, and SARS-CoV-2, with
simultaneous detection of two SARS-CoV-2 targets (N-gene + RdRP
gene) as recommended by the WHO1. The RSV A, RSV B
RT-PCR assay can
differentiate between respiratory syncytial virus A and
B.
Both kits can be processed in
parallel on the same plate, using the same temperature profile, and
provide results in approximately 1 hour. An internal control
(RNaseP) is included for adequate sample processing, and to monitor
RNA extraction and the presence of potential inhibitors in the
RT-PCR reaction. The AriaDxTM and AriaMxTM thermocyclers from
Agilent Technologies are validated for both assays. ABI Prism® 7500
Fast SDS and QuantStudioTM 5 from Applied Biosystems™, CFX96 Touch™
from Bio-Rad, and LightCycler® 480 II from Roche are validated for
the RSV A, RSV B RT-PCR kit.
Co-circulation of respiratory
tract viruses during the COVID-19 pandemic poses unprecedented
challenges to healthcare systems worldwide, and Eurofins
Technologies endeavours to continue to provide high quality
solutions for multi-pathogen testing.
1 World Health Organization. (2020). Diagnostic
testing for SARS-CoV-2: interim guidance, 11 September 2020. World
Health Organization.
https://apps.who.int/iris/handle/10665/334254.
For more information, please visit Eurofins Technologies
website.
About Eurofins Technologies – a fast growing provider of
diagnostic technologies in the field of immunoassays and molecular
detection methods
Building on the experience and scientific excellence of the
Eurofins Group, Eurofins Technologies is a fast growing global
provider of diagnostic technologies and industry-leading
ELISA-based instruments in the field of bioanalytical testing for
the food, feed, environmental, animal health, and clinical
diagnostics industries.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network
of 900 laboratories in over 50 countries, Eurofins’ companies offer
a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211201005406/en/
Rodrigo Berlie ir@eurofins.com
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024